EFFECTS OF USE OF OMEGA 3 IN DOXORRUBICIN-INDUCED DILATED CARDIOMYOPATHY IN EXPERIMENTAL MODEL WITH RABBITS

• Grant number: 18/06407-9
• Support Opportunities: Regular Research Grants
• Start date: April 01, 2019
• End date: June 30, 2021
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Daniel Paulino Junior
• Grantee: Daniel Paulino Junior
• Host Institution: Pró-Reitoria Adjunta de Pesquisa e Pós-Graduação. Universidade de Franca (UNIFRAN). Franca , SP, Brazil
• Associated researchers: Cristiane dos Santos Honsho ; Jessica Cristina de Barros ; Leandro Zuccolotto Crivellenti ; Ricardo Andrade Furtado

Abstract

Currently, the growing diagnosis of neoplasms in the clinical routine requires effective therapies to guarantee greater patient survival; among the main drugs used to achieve this goal, we highlight the doxorubicin, a chemotherapy used in innumerable antineoplastic therapy protocols. Its effectiveness has been well described for years, but like any drug, adverse effects are expected and cardiotoxicity is one of the most important described for this type of anthracycline. The intense release of free radicals and pro-inflammatory factors are responsible for the induction of myocardial necrosis, resulting in cardiac dilatation. Therefore, the objective of this study is to evaluate the effects of omega-3 on dilated cardiomyopathy induced by doxorubicin in rabbits, dose-response and antioxidant action against the chemotherapy under discussion. The study will be carried out in the months of May to July of 2018 with 30 harvesters, coming from the biofio of the University of Franca (UNIFRAN). After induction of cardiac dilation, the animals will be divided into 6 groups: positive control group (GCP) n = 6, negative control group (GCN) n = 6, omega control (GCO) n = 3, n = 6, treated group 2 (G2) n = 6, and treated group 3 (G3) n = 6. Blood counts, biochemical tests, micronucleus analysis, Doppler echocardiogram, electrocardiogram and troponin T and CK- (T0), 4 weeks (T1), 8 weeks (T2), 12 weeks (T3) and 16 weeks (T4). After completion of the study the animals will be euthanized following Resolution 1000 of the CFMV, dated May 11, 2012. The results will be analyzed statistically by the statistical software Graph Pad Prism®. (AU)